Drug Trial Radar · NCT07221162
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
140
Actual
Start
Dec 5, 2025
Primary completion
Nov 24, 2026
Study completion Nov 24, 2026
Sponsor
- Sponsor type
- NIH
- First posted
- Oct 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously vaccinated healthy adults. Each of the study sites will be assigned to enroll either only participants who will receive IM administration (up to 5 sites) or only participants who will receive IN administration (up to 5 sites); no site will administer both IM and IN study product administrations. Within the IM and IN Arms the cohorts will be sequentially enrolled. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating one dose level of Boost-2867 without adjuvant administered IM, three dose levels of Boost-2867 with adjuvant administered IM, and three dose levels of Boost-2867 without adjuvant administered IN. A sample size of 140 participants (20 participants per dose cohort) is anticipated. To evaluate for early safety signals for this first-in-human trial, study product administration of participants enrolled for IM administration and those enrolled for IN administration will proceed in a staged fashion. For Cohorts 1 (IM administration without adjuvant) and 5 (IN administration), which may be enrolled and dosed concurrently, 3 sentinel participants under 50 years of age will be enrolled in each Cohort over at least 2 days. For each of those Cohorts independently, a safety review of halting rules and clinical safety data through at least Day 8 will be conducted by the Protocol Safety Review Team (PSRT) prior to enrollment of the remainder of the cohort. Enrollment, dosing, and safety oversight for IM Cohorts 2, 3, and 4 will proceed in the same fashion as Cohort 1, except that sentinel enrollment need not be spaced over at least 2 days. Similarly, for IN Cohorts 6 and 7, enrollment and safety oversight will proceed in the same fashion as Cohort 5, except that sentinel enrollment need not be spaced over at least 2 days. The primary objectives are: 1) To evaluate the safety and reactogenicity of a single IM injection of three different antigen dose levels (5, 15, and 50 microgram) of Boost-2867 with Alhydrogel (R) (alum) and CpG 7909 adjuvants, and a single injection of 50 microgram Boost-2867 without adjuvant, in previously vaccinated healthy adults. 2) To evaluate the safety and reactogenicity of a single IN administration of three different antigen dose levels (20, 50, and 125 microgram) of Boost-2867 without adjuvant in previously vaccinated healthy adults.
Conditions
- COVID-19
Interventions
Aluminum Hydroxide SuspensionDrug
Aluminum hydroxide adjuvant.
Boost-2867Biological
Boost-2867 is a recombinant \~50 kDa SARS-CoV-2 RBD (KP.2 variant) S1 subunit joined to a human IgG1 Fc, forming a \~100 kDa homodimer.
CpG 7909Biological
CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant.
Sodium Chloride, 0.9%Other
0.9% Sodium Chloride Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of abnormal clinical safety laboratory adverse events.Time frame: Through day 8
- Occurrence of adverse events of special interest (AESIs).Time frame: Through 6 months
- Occurrence of medically attended adverse events (MAAEs).Time frame: Through 6 months
- Occurrence of new onset chronic medical conditions (NOCMCs).Time frame: Through 6 months
- Occurrence of potentially immune-mediated diseases (pIMDs)Time frame: Through 6 months
- Occurrence of Serious adverse events (SAEs).Time frame: Through 6 months
- Occurrence of solicited local adverse events (AEs).Time frame: Through 7 days
- Occurrence of solicited systemic adverse events (AEs).Time frame: Through 7 days
- Occurrence of unsolicited adverse events (AEs).Time frame: Through 28 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine
San Francisco, California
Center for Immunization Research, Johns Hopkins Bloomberg School Public Health
Baltimore, Maryland
Saint Louis University Center for Vaccine Development
St Louis, Missouri
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York
Duke Vaccine and Trials Unit
Durham, North Carolina
University of Pittsburgh - Medicine - Infectious Diseases
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Kaiser Permanente Washington Health Research Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.